Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting

Newsquawk StaffPublished 19 Mar 2026, 11:52 UTC

Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Go live — 7 days for $29.99

Go live — 7 days for £24.99

Go live — 7 days for €29.99

11:42

JPMorgan’s strategy team has cut its year-end target for the S&P 500 from 7500 to 7200 on the “geopolitical overhang”

11:36

Alibaba (9988 HK / BABA) says over the next five years, our goal is to surpass USD 100bln in combined cloud and AI external revenue

11:32

Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting

11:31

Tesla (TSLA) and Ford (F) to produce LFP batteries in the US using Chinese gear, The Information reports

11:30

PBoC Governor Pan meets Hong Kong financial secretary Paul Chan; discusses current macro economy, deepening mainland-Hong Kong financial connectivity, strengthening offshore RMB market and enhancing HK's status as an international financial center

On the Newsquawk feed at 11:32, 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)
Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation
CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option

Context

Biogen's announcement to present late-breaking data on litifilimab for cutaneous lupus erythematosus at a prominent dermatology conference highlights significant advancements in their clinical pipeline. The recent FDA Breakthrough Therapy Designation strengthens the drug’s potential and could position Biogen favorably in a market with high unmet needs, impacting investor sentiment and stock performance as expectations build ahead of the meeting.

External

Newsquawk Daily

Get both market opens in your inbox.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/14 Oct · 12:30 UTC

US Core CPI (Sep MM) 0.3% vs. Exp. 0.2% (Prev. 0.3%).

- E-mini S&P 500, after we published−0.7%

EQUITIES/12 Oct · 18:10 UTC

Bumble (BMBL) reportedly in advanced talks to go private at a USD 1bln valuation, reports WSJ.

Market, after we published+56.6%

EQUITIES/9 Oct · 17:32 UTC

Hunterbrook says Meta's (META) Muse growth slows as downloads fall; Hunterbrook holds a META short position.

Market, after we published−0.9%

EQUITIES/8 Oct · 16:43 UTC

OpenAI’s annualised revenue is about USD 20bln less than has been previously signalled, FT reports, citing sources.

Market, after we published−3.8%

EQUITIES/8 Oct · 16:43 UTC

OpenAI’s annualised revenue is about USD 20bln less than has been previously signalled, FT reports, citing sources.

Market, after we published−1.5%

EQUITIES/8 Oct · 16:43 UTC

OpenAI’s annualised revenue is about USD 20bln less than has been previously signalled, FT reports, citing sources.

Market, after we published−3.6%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Make Newsquawk a preferred source on GoogleSelect this to see Newsquawk more often in Top Stories when you search Google.

Free.

No signup, no card.

Use the Platform

Related headlines

The feed had this first.

Use the Platform